Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) EBIT (2021 - 2025)

Senti Biosciences has reported EBIT over the past 5 years, most recently at -$18.6 million for Q4 2025.

  • For Q4 2025, EBIT fell 15.27% year-over-year to -$18.6 million; the TTM value through Dec 2025 reached -$68.8 million, down 12.68%, while the annual FY2025 figure was -$68.8 million, 12.68% down from the prior year.
  • EBIT for Q4 2025 was -$18.6 million at Senti Biosciences, down from -$16.9 million in the prior quarter.
  • Over five years, EBIT peaked at -$1178.0 in Q1 2021 and troughed at -$43.9 million in Q3 2023.
  • A 5-year average of -$15.6 million and a median of -$15.7 million in 2024 define the central range for EBIT.
  • Biggest five-year swings in EBIT: plummeted 998032.43% in 2022 and later surged 65.32% in 2024.
  • Year by year, EBIT stood at -$3.9 million in 2021, then crashed by 334.42% to -$16.8 million in 2022, then decreased by 11.34% to -$18.7 million in 2023, then grew by 13.54% to -$16.2 million in 2024, then decreased by 15.27% to -$18.6 million in 2025.
  • Business Quant data shows EBIT for SNTI at -$18.6 million in Q4 2025, -$16.9 million in Q3 2025, and -$16.8 million in Q2 2025.